Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2005 Jan;81(951):20–32. doi: 10.1136/pgmj.2004.022012

Neurological channelopathies

T Graves 1, M Hanna 1
PMCID: PMC1743173  PMID: 15640425

Abstract

Ion channels are membrane-bound proteins that perform key functions in virtually all human cells. Such channels are critically important for the normal function of the excitable tissues of the nervous system, such as muscle and brain. Until relatively recently it was considered that dysfunction of ion channels in the nervous system would be incompatible with life. However, an increasing number of human diseases associated with dysfunctional ion channels are now recognised. Such neurological channelopathies are frequently genetically determined but may also arise through autoimmune mechanisms. In this article clinical, genetic, immunological, and electrophysiological aspects of this expanding group of neurological disorders are reviewed. Clinical situations in which a neurological channelopathy should enter into the differential diagnosis are highlighted. Some practical guidance on how to investigate and treat this complex group of disorders is also included.

Full Text

The Full Text of this article is available as a PDF (119.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbott G. W., Butler M. H., Bendahhou S., Dalakas M. C., Ptacek L. J., Goldstein S. A. MiRP2 forms potassium channels in skeletal muscle with Kv3.4 and is associated with periodic paralysis. Cell. 2001 Jan 26;104(2):217–231. doi: 10.1016/s0092-8674(01)00207-0. [DOI] [PubMed] [Google Scholar]
  2. Adelman J. P., Bond C. T., Pessia M., Maylie J. Episodic ataxia results from voltage-dependent potassium channels with altered functions. Neuron. 1995 Dec;15(6):1449–1454. doi: 10.1016/0896-6273(95)90022-5. [DOI] [PubMed] [Google Scholar]
  3. Audenaert D., Claes L., Ceulemans B., Löfgren A., Van Broeckhoven C., De Jonghe P. A deletion in SCN1B is associated with febrile seizures and early-onset absence epilepsy. Neurology. 2003 Sep 23;61(6):854–856. doi: 10.1212/01.wnl.0000080362.55784.1c. [DOI] [PubMed] [Google Scholar]
  4. Baulac S., Huberfeld G., Gourfinkel-An I., Mitropoulou G., Beranger A., Prud'homme J. F., Baulac M., Brice A., Bruzzone R., LeGuern E. First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene. Nat Genet. 2001 May;28(1):46–48. doi: 10.1038/ng0501-46. [DOI] [PubMed] [Google Scholar]
  5. Biervert C., Schroeder B. C., Kubisch C., Berkovic S. F., Propping P., Jentsch T. J., Steinlein O. K. A potassium channel mutation in neonatal human epilepsy. Science. 1998 Jan 16;279(5349):403–406. doi: 10.1126/science.279.5349.403. [DOI] [PubMed] [Google Scholar]
  6. Browne D. L., Gancher S. T., Nutt J. G., Brunt E. R., Smith E. A., Kramer P., Litt M. Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nat Genet. 1994 Oct;8(2):136–140. doi: 10.1038/ng1094-136. [DOI] [PubMed] [Google Scholar]
  7. Bulman D. E., Scoggan K. A., van Oene M. D., Nicolle M. W., Hahn A. F., Tollar L. L., Ebers G. C. A novel sodium channel mutation in a family with hypokalemic periodic paralysis. Neurology. 1999 Dec 10;53(9):1932–1936. doi: 10.1212/wnl.53.9.1932. [DOI] [PubMed] [Google Scholar]
  8. Ceccarelli M., Rossi B., Siciliano G., Calevro L., Tarantino E. Clinical and electrophysiological reports in a case of early onset myotonia congenita (Thomsen's disease) successfully treated with mexiletine. Acta Paediatr. 1992 May;81(5):453–455. doi: 10.1111/j.1651-2227.1992.tb12271.x. [DOI] [PubMed] [Google Scholar]
  9. Charlier C., Singh N. A., Ryan S. G., Lewis T. B., Reus B. E., Leach R. J., Leppert M. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat Genet. 1998 Jan;18(1):53–55. doi: 10.1038/ng0198-53. [DOI] [PubMed] [Google Scholar]
  10. Chen Yucai, Lu Jianjun, Pan Hong, Zhang Yuehua, Wu Husheng, Xu Keming, Liu Xiaoyan, Jiang Yuwu, Bao Xinhua, Yao Zhijian. Association between genetic variation of CACNA1H and childhood absence epilepsy. Ann Neurol. 2003 Aug;54(2):239–243. doi: 10.1002/ana.10607. [DOI] [PubMed] [Google Scholar]
  11. Davies N. P., Eunson L. H., Gregory R. P., Mills K. R., Morrison P. J., Hanna M. G. Clinical, electrophysiological, and molecular genetic studies in a new family with paramyotonia congenita. J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):504–507. doi: 10.1136/jnnp.68.4.504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Davies N. P., Eunson L. H., Samuel M., Hanna M. G. Sodium channel gene mutations in hypokalemic periodic paralysis: an uncommon cause in the UK. Neurology. 2001 Oct 9;57(7):1323–1325. doi: 10.1212/wnl.57.7.1323. [DOI] [PubMed] [Google Scholar]
  13. De Fusco M., Becchetti A., Patrignani A., Annesi G., Gambardella A., Quattrone A., Ballabio A., Wanke E., Casari G. The nicotinic receptor beta 2 subunit is mutant in nocturnal frontal lobe epilepsy. Nat Genet. 2000 Nov;26(3):275–276. doi: 10.1038/81566. [DOI] [PubMed] [Google Scholar]
  14. Denier C., Ducros A., Vahedi K., Joutel A., Thierry P., Ritz A., Castelnovo G., Deonna T., Gérard P., Devoize J. L. High prevalence of CACNA1A truncations and broader clinical spectrum in episodic ataxia type 2. Neurology. 1999 Jun 10;52(9):1816–1821. doi: 10.1212/wnl.52.9.1816. [DOI] [PubMed] [Google Scholar]
  15. Ducros A., Denier C., Joutel A., Cecillon M., Lescoat C., Vahedi K., Darcel F., Vicaut E., Bousser M. G., Tournier-Lasserve E. The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N Engl J Med. 2001 Jul 5;345(1):17–24. doi: 10.1056/NEJM200107053450103. [DOI] [PubMed] [Google Scholar]
  16. Engel Andrew G., Ohno Kinji, Sine Steven M. Congenital myasthenic syndromes: progress over the past decade. Muscle Nerve. 2003 Jan;27(1):4–25. doi: 10.1002/mus.10269. [DOI] [PubMed] [Google Scholar]
  17. Escayg A., MacDonald B. T., Meisler M. H., Baulac S., Huberfeld G., An-Gourfinkel I., Brice A., LeGuern E., Moulard B., Chaigne D. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat Genet. 2000 Apr;24(4):343–345. doi: 10.1038/74159. [DOI] [PubMed] [Google Scholar]
  18. Eunson L. H., Rea R., Zuberi S. M., Youroukos S., Panayiotopoulos C. P., Liguori R., Avoni P., McWilliam R. C., Stephenson J. B., Hanna M. G. Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability. Ann Neurol. 2000 Oct;48(4):647–656. [PubMed] [Google Scholar]
  19. Eunson L. H., Rea R., Zuberi S. M., Youroukos S., Panayiotopoulos C. P., Liguori R., Avoni P., McWilliam R. C., Stephenson J. B., Hanna M. G. Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability. Ann Neurol. 2000 Oct;48(4):647–656. [PubMed] [Google Scholar]
  20. Fukuda Taku, Motomura Masakatsu, Nakao Yoko, Shiraishi Hirokazu, Yoshimura Toshiro, Iwanaga Keisuke, Tsujihata Mitsuhiro, Eguchi Katsumi. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol. 2003 Jan;53(1):21–28. doi: 10.1002/ana.10392. [DOI] [PubMed] [Google Scholar]
  21. Graus F., Lang B., Pozo-Rosich P., Saiz A., Casamitjana R., Vincent A. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology. 2002 Sep 10;59(5):764–766. doi: 10.1212/wnl.59.5.764. [DOI] [PubMed] [Google Scholar]
  22. Griggs R. C., Engel W. K., Resnick J. S. Acetazolamide treatment of hypokalemic periodic paralysis. Prevention of attacks and improvement of persistent weakness. Ann Intern Med. 1970 Jul;73(1):39–48. doi: 10.7326/0003-4819-73-1-39. [DOI] [PubMed] [Google Scholar]
  23. Griggs R. C., Resnick J., Engel W. K. Intravenous treatment of hypokalemic periodic paralysis. Arch Neurol. 1983 Sep;40(9):539–540. doi: 10.1001/archneur.1983.04050080039005. [DOI] [PubMed] [Google Scholar]
  24. Hanna M. G., Stewart J., Schapira A. H., Wood N. W., Morgan-Hughes J. A., Murray N. M. Salbutamol treatment in a patient with hyperkalaemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene (SCN4A). J Neurol Neurosurg Psychiatry. 1998 Aug;65(2):248–250. doi: 10.1136/jnnp.65.2.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Hart I. K., Waters C., Vincent A., Newland C., Beeson D., Pongs O., Morris C., Newsom-Davis J. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol. 1997 Feb;41(2):238–246. doi: 10.1002/ana.410410215. [DOI] [PubMed] [Google Scholar]
  26. Hayward L. J., Sandoval G. M., Cannon S. C. Defective slow inactivation of sodium channels contributes to familial periodic paralysis. Neurology. 1999 Apr 22;52(7):1447–1453. doi: 10.1212/wnl.52.7.1447. [DOI] [PubMed] [Google Scholar]
  27. Heron Sarah E., Phillips Hilary A., Mulley John C., Mazarib Aziz, Neufeld Miriam Y., Berkovic Samuel F., Scheffer Ingrid E. Genetic variation of CACNA1H in idiopathic generalized epilepsy. Ann Neurol. 2004 Apr;55(4):595–596. doi: 10.1002/ana.20028. [DOI] [PubMed] [Google Scholar]
  28. Hogan K. The anesthetic myopathies and malignant hyperthermias. Curr Opin Neurol. 1998 Oct;11(5):469–476. doi: 10.1097/00019052-199810000-00009. [DOI] [PubMed] [Google Scholar]
  29. Hoskins B., Vroom F. Q., Jarrell M. A. Hyperkalemic periodic paralysis. Effects of potassium, exercise, glucose, and acetazolamide on blood chemistry. Arch Neurol. 1975 Aug;32(8):519–523. doi: 10.1001/archneur.1975.00490500039003. [DOI] [PubMed] [Google Scholar]
  30. Howard Heidi C., Mount David B., Rochefort Daniel, Byun Nellie, Dupré Nicolas, Lu Jianming, Fan Xuemo, Song Luyan, Rivière Jean-Baptiste, Prévost Claude. The K-Cl cotransporter KCC3 is mutant in a severe peripheral neuropathy associated with agenesis of the corpus callosum. Nat Genet. 2002 Oct 7;32(3):384–392. doi: 10.1038/ng1002. [DOI] [PubMed] [Google Scholar]
  31. Iles D. E., Lehmann-Horn F., Scherer S. W., Tsui L. C., Olde Weghuis D., Suijkerbuijk R. F., Heytens L., Mikala G., Schwartz A., Ellis F. R. Localization of the gene encoding the alpha 2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum Mol Genet. 1994 Jun;3(6):969–975. doi: 10.1093/hmg/3.6.969. [DOI] [PubMed] [Google Scholar]
  32. Junker J., Haverkamp W., Schulze-Bahr E., Eckardt L., Paulus W., Kiefer R. Amiodarone and acetazolamide for the treatment of genetically confirmed severe Andersen syndrome. Neurology. 2002 Aug 13;59(3):466–466. doi: 10.1212/wnl.59.3.466. [DOI] [PubMed] [Google Scholar]
  33. Jurkat-Rott K., Lehmann-Horn F., Elbaz A., Heine R., Gregg R. G., Hogan K., Powers P. A., Lapie P., Vale-Santos J. E., Weissenbach J. A calcium channel mutation causing hypokalemic periodic paralysis. Hum Mol Genet. 1994 Aug;3(8):1415–1419. doi: 10.1093/hmg/3.8.1415. [DOI] [PubMed] [Google Scholar]
  34. Jurkat-Rott K., McCarthy T., Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve. 2000 Jan;23(1):4–17. doi: 10.1002/(sici)1097-4598(200001)23:1<4::aid-mus3>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  35. Khosravani Houman, Altier Christophe, Simms Brett, Hamming Kevin S., Snutch Terrance P., Mezeyova Janette, McRory John E., Zamponi Gerald W. Gating effects of mutations in the Cav3.2 T-type calcium channel associated with childhood absence epilepsy. J Biol Chem. 2004 Jan 16;279(11):9681–9684. doi: 10.1074/jbc.C400006200. [DOI] [PubMed] [Google Scholar]
  36. Koch M. C., Steinmeyer K., Lorenz C., Ricker K., Wolf F., Otto M., Zoll B., Lehmann-Horn F., Grzeschik K. H., Jentsch T. J. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science. 1992 Aug 7;257(5071):797–800. doi: 10.1126/science.1379744. [DOI] [PubMed] [Google Scholar]
  37. Kubisch C., Schmidt-Rose T., Fontaine B., Bretag A. H., Jentsch T. J. ClC-1 chloride channel mutations in myotonia congenita: variable penetrance of mutations shifting the voltage dependence. Hum Mol Genet. 1998 Oct;7(11):1753–1760. doi: 10.1093/hmg/7.11.1753. [DOI] [PubMed] [Google Scholar]
  38. Liguori R., Vincent A., Clover L., Avoni P., Plazzi G., Cortelli P., Baruzzi A., Carey T., Gambetti P., Lugaresi E. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain. 2001 Dec;124(Pt 12):2417–2426. doi: 10.1093/brain/124.12.2417. [DOI] [PubMed] [Google Scholar]
  39. MacLennan D. H., Otsu K., Fujii J., Zorzato F., Phillips M. S., O'Brien P. J., Archibald A. L., Britt B. A., Gillard E. F., Worton R. G. The role of the skeletal muscle ryanodine receptor gene in malignant hyperthermia. Symp Soc Exp Biol. 1992;46:189–201. [PubMed] [Google Scholar]
  40. Manning B. M., Quane K. A., Ording H., Urwyler A., Tegazzin V., Lehane M., O'Halloran J., Hartung E., Giblin L. M., Lynch P. J. Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation. Am J Hum Genet. 1998 Mar;62(3):599–609. doi: 10.1086/301748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Monnier N., Procaccio V., Stieglitz P., Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet. 1997 Jun;60(6):1316–1325. doi: 10.1086/515454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Monnier N., Romero N. B., Lerale J., Nivoche Y., Qi D., MacLennan D. H., Fardeau M., Lunardi J. An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor. Hum Mol Genet. 2000 Nov 1;9(18):2599–2608. doi: 10.1093/hmg/9.18.2599. [DOI] [PubMed] [Google Scholar]
  43. Moslehi R., Langlois S., Yam I., Friedman J. M. Linkage of malignant hyperthermia and hyperkalemic periodic paralysis to the adult skeletal muscle sodium channel (SCN4A) gene in a large pedigree. Am J Med Genet. 1998 Feb 26;76(1):21–27. [PubMed] [Google Scholar]
  44. Munsat T. L. Therapy of myotonia. A double-blind evaluation of diphenylhydantoin, procainamide, and placebo. Neurology. 1967 Apr;17(4):359–367. doi: 10.1212/wnl.17.4.359. [DOI] [PubMed] [Google Scholar]
  45. Nakao Y. K., Motomura M., Suenaga A., Nakamura T., Yoshimura T., Tsujihata M., Mori M., Itoh M., Nagataki S. Specificity of omega-conotoxin MVIIC-binding and -blocking calcium channel antibodies in Lambert-Eaton myasthenic syndrome. J Neurol. 1999 Jan;246(1):38–44. doi: 10.1007/s004150050303. [DOI] [PubMed] [Google Scholar]
  46. Ophoff R. A., Terwindt G. M., Vergouwe M. N., van Eijk R., Oefner P. J., Hoffman S. M., Lamerdin J. E., Mohrenweiser H. W., Bulman D. E., Ferrari M. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996 Nov 1;87(3):543–552. doi: 10.1016/s0092-8674(00)81373-2. [DOI] [PubMed] [Google Scholar]
  47. Ophoff R. A., Terwindt G. M., Vergouwe M. N., van Eijk R., Oefner P. J., Hoffman S. M., Lamerdin J. E., Mohrenweiser H. W., Bulman D. E., Ferrari M. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996 Nov 1;87(3):543–552. doi: 10.1016/s0092-8674(00)81373-2. [DOI] [PubMed] [Google Scholar]
  48. Plaster N. M., Tawil R., Tristani-Firouzi M., Canún S., Bendahhou S., Tsunoda A., Donaldson M. R., Iannaccone S. T., Brunt E., Barohn R. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell. 2001 May 18;105(4):511–519. doi: 10.1016/s0092-8674(01)00342-7. [DOI] [PubMed] [Google Scholar]
  49. Pozo-Rosich Patricia, Clover Linda, Saiz Albert, Vincent Angela, Graus Francesc. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol. 2003 Oct;54(4):530–533. doi: 10.1002/ana.10713. [DOI] [PubMed] [Google Scholar]
  50. Ptácek L. J., George A. L., Jr, Barchi R. L., Griggs R. C., Riggs J. E., Robertson M., Leppert M. F. Mutations in an S4 segment of the adult skeletal muscle sodium channel cause paramyotonia congenita. Neuron. 1992 May;8(5):891–897. doi: 10.1016/0896-6273(92)90203-p. [DOI] [PubMed] [Google Scholar]
  51. Ptácek L. J., George A. L., Jr, Griggs R. C., Tawil R., Kallen R. G., Barchi R. L., Robertson M., Leppert M. F. Identification of a mutation in the gene causing hyperkalemic periodic paralysis. Cell. 1991 Nov 29;67(5):1021–1027. doi: 10.1016/0092-8674(91)90374-8. [DOI] [PubMed] [Google Scholar]
  52. Ptácek L. J., George A. L., Jr, Griggs R. C., Tawil R., Kallen R. G., Barchi R. L., Robertson M., Leppert M. F. Identification of a mutation in the gene causing hyperkalemic periodic paralysis. Cell. 1991 Nov 29;67(5):1021–1027. doi: 10.1016/0092-8674(91)90374-8. [DOI] [PubMed] [Google Scholar]
  53. Ptácek L. J., Tawil R., Griggs R. C., Engel A. G., Layzer R. B., Kwieciński H., McManis P. G., Santiago L., Moore M., Fouad G. Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell. 1994 Jun 17;77(6):863–868. doi: 10.1016/0092-8674(94)90135-x. [DOI] [PubMed] [Google Scholar]
  54. Ptáek L. J., Tawil R., Griggs R. C., Meola G., McManis P., Barohn R. J., Mendell J. R., Harris C., Spitzer R., Santiago F. Sodium channel mutations in acetazolamide-responsive myotonia congenita, paramyotonia congenita, and hyperkalemic periodic paralysis. Neurology. 1994 Aug;44(8):1500–1503. doi: 10.1212/wnl.44.8.1500. [DOI] [PubMed] [Google Scholar]
  55. Quane K. A., Keating K. E., Manning B. M., Healy J. M., Monsieurs K., Heffron J. J., Lehane M., Heytens L., Krivosic-Horber R., Adnet P. Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis and heterogeneity studies. Hum Mol Genet. 1994 Mar;3(3):471–476. doi: 10.1093/hmg/3.3.471. [DOI] [PubMed] [Google Scholar]
  56. Ricker K., Moxley R. T., 3rd, Heine R., Lehmann-Horn F. Myotonia fluctuans. A third type of muscle sodium channel disease. Arch Neurol. 1994 Nov;51(11):1095–1102. doi: 10.1001/archneur.1994.00540230033009. [DOI] [PubMed] [Google Scholar]
  57. Riggs J. E., Griggs R. C., Moxley R. T., 3rd, Lewis E. D. Acute effects of acetazolamide in hyperkalemic periodic paralysis. Neurology. 1981 Jun;31(6):725–729. doi: 10.1212/wnl.31.6.725. [DOI] [PubMed] [Google Scholar]
  58. Robinson R. L., Curran J. L., Ellis F. R., Halsall P. J., Hall W. J., Hopkins P. M., Iles D. E., West S. P., Shaw M. A. Multiple interacting gene products may influence susceptibility to malignant hyperthermia. Ann Hum Genet. 2000 Jul;64(Pt 4):307–320. doi: 10.1017/S0003480000008186. [DOI] [PubMed] [Google Scholar]
  59. Robinson R. L., Monnier N., Wolz W., Jung M., Reis A., Nuernberg G., Curran J. L., Monsieurs K., Stieglitz P., Heytens L. A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees. Hum Mol Genet. 1997 Jun;6(6):953–961. doi: 10.1093/hmg/6.6.953. [DOI] [PubMed] [Google Scholar]
  60. Sansone V., Griggs R. C., Meola G., Ptácek L. J., Barohn R., Iannaccone S., Bryan W., Baker N., Janas S. J., Scott W. Andersen's syndrome: a distinct periodic paralysis. Ann Neurol. 1997 Sep;42(3):305–312. doi: 10.1002/ana.410420306. [DOI] [PubMed] [Google Scholar]
  61. Scheffer I. E., Berkovic S. F. Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clinical phenotypes. Brain. 1997 Mar;120(Pt 3):479–490. doi: 10.1093/brain/120.3.479. [DOI] [PubMed] [Google Scholar]
  62. Scheffer I. E., Bhatia K. P., Lopes-Cendes I., Fish D. R., Marsden C. D., Andermann E., Andermann F., Desbiens R., Keene D., Cendes F. Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain. 1995 Feb;118(Pt 1):61–73. doi: 10.1093/brain/118.1.61. [DOI] [PubMed] [Google Scholar]
  63. Shams'ili Setareh, Grefkens Joost, de Leeuw Bertie, van den Bent Martin, Hooijkaas Herbert, van der Holt Bronno, Vecht Charles, Sillevis Smitt Peter. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003 Jun;126(Pt 6):1409–1418. doi: 10.1093/brain/awg133. [DOI] [PubMed] [Google Scholar]
  64. Shiang R., Ryan S. G., Zhu Y. Z., Hahn A. F., O'Connell P., Wasmuth J. J. Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. Nat Genet. 1993 Dec;5(4):351–358. doi: 10.1038/ng1293-351. [DOI] [PubMed] [Google Scholar]
  65. Shiang R., Ryan S. G., Zhu Y. Z., Hahn A. F., O'Connell P., Wasmuth J. J. Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. Nat Genet. 1993 Dec;5(4):351–358. doi: 10.1038/ng1293-351. [DOI] [PubMed] [Google Scholar]
  66. Shillito P., Molenaar P. C., Vincent A., Leys K., Zheng W., van den Berg R. J., Plomp J. J., van Kempen G. T., Chauplannaz G., Wintzen A. R. Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol. 1995 Nov;38(5):714–722. doi: 10.1002/ana.410380505. [DOI] [PubMed] [Google Scholar]
  67. Singh N. A., Charlier C., Stauffer D., DuPont B. R., Leach R. J., Melis R., Ronen G. M., Bjerre I., Quattlebaum T., Murphy J. V. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet. 1998 Jan;18(1):25–29. doi: 10.1038/ng0198-25. [DOI] [PubMed] [Google Scholar]
  68. Steinlein O. K., Mulley J. C., Propping P., Wallace R. H., Phillips H. A., Sutherland G. R., Scheffer I. E., Berkovic S. F. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet. 1995 Oct;11(2):201–203. doi: 10.1038/ng1095-201. [DOI] [PubMed] [Google Scholar]
  69. Steinlein O. K., Mulley J. C., Propping P., Wallace R. H., Phillips H. A., Sutherland G. R., Scheffer I. E., Berkovic S. F. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet. 1995 Oct;11(2):201–203. doi: 10.1038/ng1095-201. [DOI] [PubMed] [Google Scholar]
  70. Sternberg D., Maisonobe T., Jurkat-Rott K., Nicole S., Launay E., Chauveau D., Tabti N., Lehmann-Horn F., Hainque B., Fontaine B. Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A. Brain. 2001 Jun;124(Pt 6):1091–1099. doi: 10.1093/brain/124.6.1091. [DOI] [PubMed] [Google Scholar]
  71. Stewart S. L., Hogan K., Rosenberg H., Fletcher J. E. Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia. Clin Genet. 2001 Mar;59(3):178–184. doi: 10.1034/j.1399-0004.2001.590306.x. [DOI] [PubMed] [Google Scholar]
  72. Sudbrak R., Procaccio V., Klausnitzer M., Curran J. L., Monsieurs K., van Broeckhoven C., Ellis R., Heyetens L., Hartung E. J., Kozak-Ribbens G. Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. Am J Hum Genet. 1995 Mar;56(3):684–691. [PMC free article] [PubMed] [Google Scholar]
  73. Sugawara T., Tsurubuchi Y., Agarwala K. L., Ito M., Fukuma G., Mazaki-Miyazaki E., Nagafuji H., Noda M., Imoto K., Wada K. A missense mutation of the Na+ channel alpha II subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures causes channel dysfunction. Proc Natl Acad Sci U S A. 2001 May 22;98(11):6384–6389. doi: 10.1073/pnas.111065098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Tawil R., McDermott M. P., Brown R., Jr, Shapiro B. C., Ptacek L. J., McManis P. G., Dalakas M. C., Spector S. A., Mendell J. R., Hahn A. F. Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann Neurol. 2000 Jan;47(1):46–53. [PubMed] [Google Scholar]
  75. Tristani-Firouzi Martin, Jensen Judy L., Donaldson Matthew R., Sansone Valeria, Meola Giovanni, Hahn Angelika, Bendahhou Said, Kwiecinski Hubert, Fidzianska Anna, Plaster Nikki. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest. 2002 Aug;110(3):381–388. doi: 10.1172/JCI15183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Wallace R. H., Marini C., Petrou S., Harkin L. A., Bowser D. N., Panchal R. G., Williams D. A., Sutherland G. R., Mulley J. C., Scheffer I. E. Mutant GABA(A) receptor gamma2-subunit in childhood absence epilepsy and febrile seizures. Nat Genet. 2001 May;28(1):49–52. doi: 10.1038/ng0501-49. [DOI] [PubMed] [Google Scholar]
  77. Wallace R. H., Wang D. W., Singh R., Scheffer I. E., George A. L., Jr, Phillips H. A., Saar K., Reis A., Johnson E. W., Sutherland G. R. Febrile seizures and generalized epilepsy associated with a mutation in the Na+-channel beta1 subunit gene SCN1B. Nat Genet. 1998 Aug;19(4):366–370. doi: 10.1038/1252. [DOI] [PubMed] [Google Scholar]
  78. Weckbecker K., Würz A., Mohammadi B., Mansuroglu T., George A. L., Jr, Lerche H., Dengler R., Lehmann-Horn F., Mitrovic N. Different effects of mexiletine on two mutant sodium channels causing paramyotonia congenita and hyperkalemic periodic paralysis. Neuromuscul Disord. 2000 Jan;10(1):31–39. doi: 10.1016/s0960-8966(99)00060-7. [DOI] [PubMed] [Google Scholar]
  79. Wu Fen-Fen, Ryan Aisling, Devaney Joseph, Warnstedt Maike, Korade-Mirnics Zeljka, Poser Barbara, Escriva Maria Jose, Pegoraro Elena, Yee Audrey S., Felice Kevin J. Novel CLCN1 mutations with unique clinical and electrophysiological consequences. Brain. 2002 Nov;125(Pt 11):2392–2407. doi: 10.1093/brain/awf246. [DOI] [PubMed] [Google Scholar]
  80. Zhao F., Li P., Chen S. R., Louis C. F., Fruen B. R. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem. 2001 Feb 5;276(17):13810–13816. doi: 10.1074/jbc.M006104200. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES